HaiHe forms joint venture with CSPC, narrows focus to oncology
Shanghai HaiHe Biopharma Co. Ltd. (Shanghai, China) formed a joint venture with CSPC Pharmaceutical Group Ltd. (HKSE:1093) to develop and commercialize five of HaiHe’s programs, mostly outside of oncology. Financial terms were not disclosed.
HaiHe is aiming to focus primarily on cancer, CEO RuiPing Dong told BioCentury. Last week, the company raised $146.6 million to advance its cancer candidates (see "HaiHe Raises $147M in Series B to Advance Cancer Candidates")...
BCIQ Target Profiles
Cyclin dependent kinase 4 (CDK4)
Cyclin dependent kinase 6 (CDK6)
Fibroblast growth factor (FGF) receptor 1 (FGFR1) (CD331)
Fibroblast growth factor (FGF) receptor 2 (FGFR2) (KGFR) (CD332)
Fibroblast growth factor (FGF) receptor 3 (FGFR3) (CD333)
Prostaglandin E2 (PGE2) receptor EP4 subtype (Prostanoid EP4 receptor) (PTGER4)